

Anthera Pharmaceuticals Inc
 Form 3
 April 05, 2016

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
 OMB Number: 3235-0104
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Â Pennington James (Last) (First) (Middle) 25801 INDUSTRIAL BLVD., SUITE B (Street) HAYWARD, Â CA Â 94545 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 04/01/2016	3. Issuer Name and Ticker or Trading Symbol Anthera Pharmaceuticals Inc [ANTH]	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) Interim Chief Medical Officer	5. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
---	--	--	--	--	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	17,688	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) Title	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
---	---	---	--	---	--

Edgar Filing: Anthera Pharmaceuticals Inc - Form 3

	Date Exercisable	Expiration Date		Amount or Number of Shares		or Indirect (I) (Instr. 5)	
Stock option (right to buy)	10/24/2017	10/24/2017	Common Stock	4,746	\$ 2.08	D	Â
Stock option (right to buy)	02/18/2009	02/18/2019	Common Stock	3,651	\$ 12.08	D	Â
Stock option (right to buy)	Â (1)	05/17/2023	Common Stock	25,000	\$ 4.88	D	Â
Stock option (right to buy)	Â (2)	01/01/2025	Common Stock	20,000	\$ 1.58	D	Â
Stock option (right to buy)	Â (3)	05/21/2025	Common Stock	70,000	\$ 4.75	D	Â
Stock option (right to buy)	Â (4)	01/15/2026	Common Stock	20,000	\$ 3.44	D	Â
Stock option (right to buy)	Â (5)	03/04/2026	Common Stock	45,000	\$ 3.75	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Pennington James 25801 INDUSTRIAL BLVD., SUITE B HAYWARD, CA 94545	Â	Â	Â Interim Chief Medical Officer	Â

Signatures

/s/ James
Pennington

04/05/2016

**Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This stock option vests annually over four years beginning March 25, 2013 ("the Vesting Start Date"). The Stock Option is completely vested on the fourth anniversary of the vesting start date.
 - (2) This stock option vests annually over four years beginning January 1, 2015 ("the Vesting Start Date"). The Stock Option is completely vested on the fourth anniversary of the vesting start date.
 - (3) This stock option vests annually over four years beginning January 1, 2015 ("the Vesting Start Date"). The Stock Option is completely vested on the fourth anniversary of the vesting start date.
 - (4) This stock option vests annually over four years beginning January 1, 2016 ("the Vesting Start Date"). The Stock Option is completely vested on the fourth anniversary of the vesting start date.
 - (5) This stock option vests monthly over six months beginning April 1, 2016 ("the Vesting Start Date"). The Stock Option is completely vested on September 30, 2016

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Edgar Filing: Anthera Pharmaceuticals Inc - Form 3

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.